Viscoli CM, Inzucchi SE, Young LH, Insogna KL, Conwit R, Furie KL, et al
Structural conservation of insulin/IGF signalling axis at the insulin receptors level in Drosophila and humans
A TGA spokesperson added that while anyone can search the publicly available Database of Adverse Events Notifications, reporting of an adverse event does not necessarily mean that a causal link with the medicine is established
Orforglipron (LY3502970) is a non-peptide GLP-1R agonist currently in clinical development that has demonstrated promising effects on glycemic control and body weight reduction, highlighting the continued expansion of GLP-1-based therapeutic strategies [4]
When semaglutide stops, ghrelin and other appetite hormones rebound while satiety signals drop, so hunger can feel sharper than it did before treatment